

PART VI- Summary of the Risk management plan

Summary of risk management plan for Mercaptopurina SILVER Pharma 50 mg comprimidos.

I. The medicine and what it is used for

Mercaptopurina Silver Pharma 50mg comprimidos is indicated for the treatment of acute leukaemia. It may be utilised in remission induction and it is particularly indicated for maintenance therapy in acute lymphoblastic leukaemia and acute myelogenous leukaemia. It contains mercaptopurine as the active substance, and it is given by oral administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Mercaptopurina Silver Pharma 50mg comprimidos, together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

II.A List of important risks and missing information

Important risks of Mercaptopurina Silver Pharma 50mg comprimidos are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential.

Identified risks are concerns for which there is sufficient proof of a link with the use of Mercaptopurina Silver Pharma 50mg comprimidos. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation.

Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Summary of safety concerns	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Mercaptopurina Silver Pharma 50mg comprimidos.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Mercaptopurina Silver Pharma 50mg comprimidos.